Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T.

Mol Ther. 2012 Jan;20(1):73-83. doi: 10.1038/mt.2011.177. Epub 2011 Sep 13.

2.

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes.

Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD.

J Virol. 2000 Feb;74(3):1524-32.

3.

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.

Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV.

Gene Ther. 2015 Feb;22(2):116-26. doi: 10.1038/gt.2014.115. Epub 2014 Dec 11.

4.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Mar 1;107(5):1810-7. Epub 2005 Oct 25.

5.
6.
8.

Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.

Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R.

Gene Ther. 2013 Apr;20(4):450-9. doi: 10.1038/gt.2012.101. Epub 2013 Jan 10. Erratum in: Gene Ther. 2013 Apr;20(4):465.

9.

Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.

György B, Fitzpatrick Z, Crommentuijn MH, Mu D, Maguire CA.

Biomaterials. 2014 Aug;35(26):7598-609. doi: 10.1016/j.biomaterials.2014.05.032. Epub 2014 Jun 7.

10.

Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.

Palomeque J, Chemaly ER, Colosi P, Wellman JA, Zhou S, Del Monte F, Hajjar RJ.

Gene Ther. 2007 Jul;14(13):989-97. Epub 2007 Jan 25. Erratum in: Gene Ther. 2007 Jul;14(13):1055.

PMID:
17251988
11.

Characterization of naturally-occurring humoral immunity to AAV in sheep.

Tellez J, Van Vliet K, Tseng YS, Finn JD, Tschernia N, Almeida-Porada G, Arruda VR, Agbandje-McKenna M, Porada CD.

PLoS One. 2013 Sep 24;8(9):e75142. doi: 10.1371/journal.pone.0075142. eCollection 2013.

12.

Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.

Harrington EA, Sloan JL, Manoli I, Chandler RJ, Schneider M, McGuire PJ, Calcedo R, Wilson JM, Venditti CP.

Hum Gene Ther. 2016 May;27(5):345-53. doi: 10.1089/hum.2015.092. Epub 2016 Mar 22.

13.
14.

Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.

Shin JH, Yue Y, Smith B, Duan D.

Hum Gene Ther. 2012 Mar;23(3):287-94. doi: 10.1089/hum.2011.125. Epub 2012 Jan 11.

15.

Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.

Calcedo R, Franco J, Qin Q, Richardson DW, Mason JB, Boyd S, Wilson JM.

Hum Gene Ther Methods. 2015 Jun;26(3):103-5. doi: 10.1089/hgtb.2015.082.

16.

The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.

Mimuro J, Mizukami H, Shima M, Matsushita T, Taki M, Muto S, Higasa S, Sakai M, Ohmori T, Madoiwa S, Ozawa K, Sakata Y.

J Med Virol. 2014 Nov;86(11):1990-7. doi: 10.1002/jmv.23818. Epub 2013 Oct 17.

PMID:
24136735
17.

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.

Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE; Joint Outcome Study Investigators.

Gene Ther. 2012 Mar;19(3):288-94. doi: 10.1038/gt.2011.90. Epub 2011 Jun 23.

PMID:
21697954
18.

Adeno-associated virus antibody profiles in newborns, children, and adolescents.

Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM.

Clin Vaccine Immunol. 2011 Sep;18(9):1586-8. doi: 10.1128/CVI.05107-11. Epub 2011 Jul 20.

19.

Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver.

Murphy SL, Li H, Zhou S, Schlachterman A, High KA.

Mol Ther. 2008 Jan;16(1):138-45. Epub 2007 Oct 23. Erratum in: Mol Ther. 2008 Mar;16(3):633. High, Katherine [corrected to High, Katherine A].

20.

Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer.

Li C, Wu S, Albright B, Hirsch M, Li W, Tseng YS, Agbandje-McKenna M, McPhee S, Asokan A, Samulski RJ.

Mol Ther. 2016 Feb;24(1):53-65. doi: 10.1038/mt.2015.134. Epub 2015 Jul 29.

Supplemental Content

Support Center